China SXT Pharmaceuticals
SXTC
1 hedge funds and large institutions have $6.97M invested in China SXT Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
2,295% more capital invested
Capital invested by funds: $291K → $6.97M (+$6.68M)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$182K |
| 2 |
SIM
Spark Investment Management
New York
|
-$94K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Hudson Bay Capital Management
Stamford,
Connecticut
| $6.8M | +$11M | +1 | New |
|
2
Invesco
Atlanta,
Georgia
| $88K | – | – | – |
|
3
Jane Street
New York
| $72K | – | – | – |
|
4
UBS Group
Zurich,
Switzerland
| $7K | – | – | – |
|
|
SIM
5
Spark Investment Management
New York
| – | -$94K | – | – |
|
|
VF
6
Virtu Financial
New York
| – | -$182K | – | – |
|
SXTC Hedge Fund Activity: Q2 2019 in Review
1 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q2 2019, worth a combined $6.97M — up 2,295% from $291K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SXTC positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $11M. The largest seller was Virtu Financial, cutting an estimated $182K.
- 1 institutional investor held China SXT Pharmaceuticals (SXTC) as of Q2 2019, up from 0 in Q1 2019.
- Funds reported $6.97M of China SXT Pharmaceuticals stock for Q2 2019, up 2,295% quarter-over-quarter.
- 1 fund opened new China SXT Pharmaceuticals positions in Q2 2019 and 0 closed out, a net change of +1 holder.
- The largest China SXT Pharmaceuticals buyer in Q2 2019 was Hudson Bay Capital Management, an estimated $11M added.
- The largest China SXT Pharmaceuticals seller in Q2 2019 was Virtu Financial, an estimated $182K sold.
Based on aggregated 13F filings for Q2 2019.